We can only imagine how the Trump administration’s internal conversation about lowering the price of pharmaceuticals has been going.
President Trump campaigned on the issue and has repeatedly made bold promises to bring down the price of drugs since taking office. Trump chose a solid issue to stump on. Polls show that voters are furious about the cost of medicine and want lower prices to be a top priority in Washington.
Fulfilling these promises is another story. As Trump’s aides may have explained to him, sparking meaningful decreases in drug costs within a short period of time — say, the first few years of a presidential administration — would require government intervention in the pharmaceutical market and supply chain. Lawmakers may need to pass sweeping legislation, and new regulations are something that most Republicans, the health lobby and Trump himself generally oppose.
So, Trump tapped Alex Azar, a former Bush administration official who spent several years working as a top pharmaceutical executive, to come up with a plan. After weeks of delay and with much fanfare, Trump and Azar finally released a blueprint for lowering drug costs in May. Trump began making bold claims that drug makers would lower their prices within weeks in response.
It never happened. Biotech and pharmaceutical stock prices jumped after the blueprint was released because investors saw little long-term threat to their profit margins. By late June and early July, drug companies were once again raising prices for hundreds of drugs, just as they do every year.
So, predictably, Trump lashed out on Twitter earlier this week, saying Pfizer “and others” should be “ashamed” for raising drug prices “for no reason.” Then he got the company’s CEO on the phone. Pfizer caved and agreed to delay price hikes on 100 drugs until the blueprint “goes into effect” or the end of the year — whichever comes sooner. This would give the president “an opportunity to work on his blueprint,” according to the company’s statement.
Trump chalked the concession up to a win, but critics quickly pointed out that Pfizer did not lower any prices, nor does the agreement prevent other companies from continuing to raise prices. For example, the drug maker Celgene just hiked the price of the life-extending cancer drug Revlimid by 5 percent and has raised the price a total of 25 percent over the past 18 months, according to the non-partisan advocacy group Patients for Affordable Drugs.
“Pfizer’s PR stunt is unenforceable, unverifiable and non-binding,” said Charles Fournier, vice president of the Type 1 Diabetes Defense Foundation, a group that fights for lower insulin prices, in an email. “There is no substitute for full rebate pass-through and net price disclosure.”
Patients for Affordable Drugs President David Mitchell said he was “glad” to see Trump get tough on Pfizer, but one conversation with one pharmaceutical executive is not enough to fix the problem.
“There are other companies that have increased prices and could use the pressure of a Presidential tweet,” Mitchell said in a statement. “But one-off tweets do not fix the systemic problems we have with drug prices. We need long-term structural action to provide enduring relief.”
Sen. Ron Wyden (D-Oregon) went even further, saying Trump’s deal with Pfizer is just the kind of “secret, sweetheart arrangement” that defines the broken drug pricing system.
“Instead of proposing meaningful changes that result in lower costs for families and taxpayers, Trump and his Administration are busy scoring cheap PR points that don’t address the fundamental challenges that lead to higher prices every year,” Wyden said in a statement.
Wyden is referring to the system of secret rebating agreements struck between drug companies, pharmacy benefit managers and insurance companies that systematically increase the sticker price of certain drugs. As Truthout has reported, all the players in this supply chain profit from higher drug prices, and they have used the system’s sheer opacity to blame each other for rising costs at the pharmacy, particularly for those with little or no health coverage.
In separate letters sent to Pfizer and Azar this week, Wyden demanded to know the details of the deal Trump struck with Pfizer. Did Trump agree to give Pfizer special consideration as his administration works to implement the drug-pricing blueprint in exchange for the price hike delay? And what about the federal statute that prohibits the government from negotiating drug prices in the Medicare Part D program, which Trump proposed lifting during his campaign but later backed away from? Trump can’t formally reject a proposal to repeal this rule and then attempt to negotiate drug prices himself, Wyden argues.
Wyden also asked Pfizer how its decision to delay the price hikes would impact its secret rebate negotiations with pharmacy benefit managers and insurance companies. Congressional Democrats and several states want to shed light on these backroom agreements, and Wyden has introduced legislation that would require transparency for companies participating in the Medicare program.
There is already evidence that such transparency can bring prices down. California passed an aggressive law requiring drug companies to notify insurers and government health plans at least 60 days before issuing major price hikes, and Bloomberg reported this week that a handful of drug makers have reduced or canceled previously announced price increases as a result.
The pharmaceutical industry has sued to block the law, arguing that watchdogs should examine how insurance companies distribute savings from rebate payments through their health plans instead. During a recent congressional testimony, Azar said that drug makers could lose a competitive advantage if they lower their prices, because high prices allow them to pay higher rebates to pharmacy benefit managers and insurance companies that control access to their customers.
Azar has threatened to take a “hard look” at the secret rebating system if all the players involved can’t figure out a solution for lowering prices on their own, but cautioned reexamining the entire drug supply chain would take time and potentially action from Congress. He has also threatened drug companies with rules requiring they put their drug prices in TV ads. As of now, however, these are just threats, and drug companies don’t appear to be responding.
Trump took matters into his own hands this week, a good sign that he is not interested in waiting for prices to come down. Meanwhile, Wyden’s office says that his transparency bill remains stuck in committee because Republicans refuse to support it. Maybe Trump should send some angry tweets their way as well.
Truthout Is Preparing to Meet Trump’s Agenda With Resistance at Every Turn
Dear Truthout Community,
If you feel rage, despondency, confusion and deep fear today, you are not alone. We’re feeling it too. We are heartsick. Facing down Trump’s fascist agenda, we are desperately worried about the most vulnerable people among us, including our loved ones and everyone in the Truthout community, and our minds are racing a million miles a minute to try to map out all that needs to be done.
We must give ourselves space to grieve and feel our fear, feel our rage, and keep in the forefront of our mind the stark truth that millions of real human lives are on the line. And simultaneously, we’ve got to get to work, take stock of our resources, and prepare to throw ourselves full force into the movement.
Journalism is a linchpin of that movement. Even as we are reeling, we’re summoning up all the energy we can to face down what’s coming, because we know that one of the sharpest weapons against fascism is publishing the truth.
There are many terrifying planks to the Trump agenda, and we plan to devote ourselves to reporting thoroughly on each one and, crucially, covering the movements resisting them. We also recognize that Trump is a dire threat to journalism itself, and that we must take this seriously from the outset.
Last week, the four of us sat down to have some hard but necessary conversations about Truthout under a Trump presidency. How would we defend our publication from an avalanche of far right lawsuits that seek to bankrupt us? How would we keep our reporters safe if they need to cover outbreaks of political violence, or if they are targeted by authorities? How will we urgently produce the practical analysis, tools and movement coverage that you need right now — breaking through our normal routines to meet a terrifying moment in ways that best serve you?
It will be a tough, scary four years to produce social justice-driven journalism. We need to deliver news, strategy, liberatory ideas, tools and movement-sparking solutions with a force that we never have had to before. And at the same time, we desperately need to protect our ability to do so.
We know this is such a painful moment and donations may understandably be the last thing on your mind. But we must ask for your support, which is needed in a new and urgent way.
We promise we will kick into an even higher gear to give you truthful news that cuts against the disinformation and vitriol and hate and violence. We promise to publish analyses that will serve the needs of the movements we all rely on to survive the next four years, and even build for the future. We promise to be responsive, to recognize you as members of our community with a vital stake and voice in this work.
Please dig deep if you can, but a donation of any amount will be a truly meaningful and tangible action in this cataclysmic historical moment.
We’re with you. Let’s do all we can to move forward together.
With love, rage, and solidarity,
Maya, Negin, Saima, and Ziggy